HD204 (Bevacizumab biosimilar)

Ulenistamab (PBP1510) is a First-in-Class antibody drug developed as a target of pancreatic adenocarcinoma up-regulated factor (PAUF) resulting in decreased autocrine and paracrine signaling implicated pancreatic cancer. It attenuates the tumorigenic potential of PAUF in both the pancreatic cancer cells an...

Pancreatic Adenocarcinoma Up-regulated Factor- PAUF is over-expressed in over 80% of pancreatic adenocarcinoma (PDAC). With our expertise in biosimilars and novel antibody drugs development and manufacturing, we are strongly positioned to tackle the unaddressed need of pancreatic cancer. Early detection an...

Ulenistamab (PBP1510) is a First-in-Class antibody drug developed as a target of pancreatic adenocarcinomaup-regulated factor (PAUF) resulting in decreased autocrine and paracrine signaling implicated pancreatic cancer.

It attenuates the tumorigenic potential of PAUF in both the pancreatic cancer ce...

PRESTIGE BIOPHARMA LTD (PBP) is a rapidly-expanding, biopharmaceutical company, with an Innovative Drug Development Platform from Discovery to CMC analysis to GMP Product Manufacturing. We are pioneers in pancreatic cancer, with novel antibody drugs and diagnostics targeting PAUF (biomarker for pancreatic cancer) under development. We also specialize in development and manufacturing of biosimilars and vaccines.

PRESTIGE BIOPHARMA LTD (PBP) is a rapidly-expanding, biopharmaceutical company, with an Innovative Drug Development Platform from Discovery to CMC analysis to GMP Product Manufacturing. We are pioneers in pancreatic cancer, with novel antibody drugs and diagnostics targeting PAUF (biomarker for pancreatic cancer) under development. We also specialize in development and manufacturing of biosimilars and vaccines.

Prestige Biopharma is one of the fastest growing biopharmaceutical companies specializing in the discovery and development of first-in-class antibody drugs, biosimilars, and vaccines.

Established in July 2015, we are committed to developing first-in-class antibody drugs to address unmet medical needs including pancreatic cancer, as well as developing high-quality and cost-competitive biosimilars to enhance patient access to affordable treatments alternatives for critical diseases. In addition, next-generation vaccines against future pandemics are in development.

With decades of R&D and operational expertise, bolstered by scientific capabilities, we are accelerating the global development and commercialisation of future biologics, operating from our Singapore headquarters, Innovative Discovery Centre (IDC) in Busan, Korea – the hub of R&D.

Pancreatic Adenocarcinoma Up-regulated Factor  ----
PAUF: Promising New Biomarker For Pancreatic CancerSecreted protein involved in pancreatic cancer progression and metastasis. Novel target for the treatment and diagnosis of pancreatic cancer.

Prestige Biopharma is one of the fastest growing biopharmaceutical companies specializing in the discovery and development of first-in-class antibody drugs, biosimilars, and vaccines.

Established in July 2015, we are committed to developing first-in-class antibody drugs to address unmet medical needs including pancreatic cancer, as well as developing high-quality and cost-competitive biosimilars to enhance patient access to affordable treatments alternatives for critical diseases. In addition, next-generation vaccines against future pandemics are in development.

Prestige Biopharma is one of the fastest growing biopharmaceutical companies specializing in the discovery and development of first-in-class antibody drugs, biosimilars, and vaccines.

Established in July 2015, we are committed to developing first-in-class antibody drugs to address unmet medical needs including pancreatic cancer, as well as developing high-quality and cost-competitive biosimilars to enhance patient access to affordable treatments alternatives for critical diseases. In addition, next-generation vaccines against future pandemics are in development.

With decades of R&D and operational expertise, bolstered by scientific capabilities, we are accelerating the global development and commercialisation of future biologics, operating from our Singapore headquarters, Innovative Discovery Centre (IDC) in Busan, Korea – the hub of R&D.